How Ph.D. was paid
$7.3M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Stock | Options | Incentive | Other | Total |
|---|---|---|---|---|---|---|---|
| Leonard S. Schleifer, M.D., Ph.D.Board co-Chair, President and Chief Executive Officer | $1,979,922 | — | — | — | $3,682,655 | $1,617,972 | $7,280,549 |
| George D. Yancopoulos, M.D., Ph.D.Board co-Chair, President and Chief Scientific Officer | $1,979,922 | — | — | — | $1,286,892 | — | $6,949,469 |
| Christopher FenimoreExecutive Vice President, Finance and Chief Financial Officer | $725,000 | — | $2,199,751 | $3,299,977 | $721,013 | $39,623 | $6,985,364 |
| Daniel P. Van PlewExecutive Vice President and General Manager, Industrial Operations and Product Supply | $983,382 | — | $2,699,728 | $4,049,757 | $965,189 | $82,207 | $8,780,263 |
| Andrew J. Murphy, Ph.D.Executive Vice President, Co-Chief Scientific Officer | $819,672 | — | $2,699,728 | $4,049,757 | $815,164 | $92,798 | $8,477,119 |
| Joseph J. LaRosaExecutive Vice President, General Counsel and Secretary | $916,062 | $1,000,000 | $1,799,334 | $2,699,810 | $911,024 | $132,740 | $7,458,970 |
What changed and why
- $7.3MCEO total compensation was $7,280,549 in 2025.
- 93%The 2025 say-on-pay proposal received 93% support from shareholders.
- $5.9BRegeneron invested $5.9B in R&D in 2025.
- 2.00%The company achieved a record-low burn rate of 2.00% in 2025.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.